CN104471406A - 用于诊断骨关节炎的方法 - Google Patents

用于诊断骨关节炎的方法 Download PDF

Info

Publication number
CN104471406A
CN104471406A CN201380037434.2A CN201380037434A CN104471406A CN 104471406 A CN104471406 A CN 104471406A CN 201380037434 A CN201380037434 A CN 201380037434A CN 104471406 A CN104471406 A CN 104471406A
Authority
CN
China
Prior art keywords
concentration
osteoarthritis
cell factor
pdgf
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380037434.2A
Other languages
English (en)
Chinese (zh)
Inventor
克丽斯塔·欧肖内西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomet Biologics LLC
Original Assignee
Biomet Biologics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomet Biologics LLC filed Critical Biomet Biologics LLC
Publication of CN104471406A publication Critical patent/CN104471406A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/49—Platelet-derived growth factor [PDGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201380037434.2A 2012-06-04 2013-06-04 用于诊断骨关节炎的方法 Pending CN104471406A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261655322P 2012-06-04 2012-06-04
US61/655,322 2012-06-04
PCT/US2013/044075 WO2013184660A1 (en) 2012-06-04 2013-06-04 Methods for diagnosing osteoarthritis

Publications (1)

Publication Number Publication Date
CN104471406A true CN104471406A (zh) 2015-03-25

Family

ID=48626668

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380037434.2A Pending CN104471406A (zh) 2012-06-04 2013-06-04 用于诊断骨关节炎的方法

Country Status (5)

Country Link
US (1) US20150141332A1 (enExample)
EP (1) EP2856171A1 (enExample)
JP (1) JP2015520383A (enExample)
CN (1) CN104471406A (enExample)
WO (1) WO2013184660A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111855999A (zh) * 2020-06-02 2020-10-30 广东省药品检验所（广东省药品质量研究所、广东省口岸药品检验所） 一种化妆品中rhEGF快速检测试纸卡、试剂盒及其检测方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2567692B1 (en) 2008-02-27 2016-04-06 Biomet Biologics, LLC Use of a device for obtaining interleukin-1 receptor antagonist rich solutions
US9895418B2 (en) 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US10208095B2 (en) 2013-03-15 2019-02-19 Biomet Manufacturing, Llc Methods for making cytokine compositions from tissues using non-centrifugal methods
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
US9878011B2 (en) 2013-03-15 2018-01-30 Biomet Biologics, Llc Treatment of inflammatory respiratory disease using biological solutions
US9758806B2 (en) 2013-03-15 2017-09-12 Biomet Biologics, Llc Acellular compositions for treating inflammatory disorders
US9950035B2 (en) 2013-03-15 2018-04-24 Biomet Biologics, Llc Methods and non-immunogenic compositions for treating inflammatory disorders
US9833474B2 (en) 2013-11-26 2017-12-05 Biomet Biologies, LLC Methods of mediating macrophage phenotypes
US10441635B2 (en) 2014-11-10 2019-10-15 Biomet Biologics, Llc Methods of treating pain using protein solutions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006023412A2 (en) * 2004-08-18 2006-03-02 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Biomarkers for osteoarthritis
CN1977049A (zh) * 2004-04-26 2007-06-06 儿童医疗中心有限公司 用于检测疾病的血小板生物标志物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120030593A1 (en) 1995-11-13 2012-02-02 Lakshmi Arunachalam Method and apparatus for enabling real-time bi-directional transactions on a network
JP4344436B2 (ja) * 1999-08-24 2009-10-14 生化学工業株式会社 変形性関節症の検出方法
DE602004030586D1 (de) * 2003-09-15 2011-01-27 Oklahoma Med Res Found Verfahren zur verwendung von cytokintests zur diagnose, behandlung und beurteilung von ankyloider spondylitis
EP2567692B1 (en) 2008-02-27 2016-04-06 Biomet Biologics, LLC Use of a device for obtaining interleukin-1 receptor antagonist rich solutions
US8753690B2 (en) 2008-02-27 2014-06-17 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
US20110306512A1 (en) * 2008-06-25 2011-12-15 Dxterity Diagnostics Gene Expression Profiling for Identification, Monitoring, and Treatment of Osteoarthritis
US20110052561A1 (en) 2009-08-27 2011-03-03 Biomet Biologics,LLC Osteolysis treatment
WO2011031553A2 (en) 2009-08-27 2011-03-17 Biomet Biologics, Llc Implantable device for production of interleukin-1 receptor antagonist

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1977049A (zh) * 2004-04-26 2007-06-06 儿童医疗中心有限公司 用于检测疾病的血小板生物标志物
WO2006023412A2 (en) * 2004-08-18 2006-03-02 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Biomarkers for osteoarthritis

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DAVID A.WALSH等: "Angiogenesis and nerve growth factor at the osteochondral junction in rheumatoid arthritis and osteoarthritis", 《RHEUMATOLOGY》, vol. 49, 26 June 2010 (2010-06-26) *
EDUARDO ANITUA等: "Relationship between investigative biomarkers and radiographic grading in patients with knee osteoarthritis", 《INTERNATIONAL JOURNAL OF RHEUMATOLOGY》, 31 December 2009 (2009-12-31) *
JENNIFER WOODELL-MAY等: "Autologous protein solution inhibits MMP-13 production by IL-1b and TNFa-stimulated human articular chondrocytes", 《JOURNAL OF ORTHOPAEDIC RESEARCH》, 15 March 2011 (2011-03-15) *
VERENA MOOS等: "Immunohistological analysis of cytokine expression in human osteoarthritic and healthy cartilage.", 《THE JOURNAL OF RHEUMATOLOGY》, vol. 26, 31 December 1999 (1999-12-31) *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111855999A (zh) * 2020-06-02 2020-10-30 广东省药品检验所（广东省药品质量研究所、广东省口岸药品检验所） 一种化妆品中rhEGF快速检测试纸卡、试剂盒及其检测方法

Also Published As

Publication number Publication date
EP2856171A1 (en) 2015-04-08
US20150141332A1 (en) 2015-05-21
WO2013184660A1 (en) 2013-12-12
JP2015520383A (ja) 2015-07-16

Similar Documents

Publication Publication Date Title
CN104471406A (zh) 用于诊断骨关节炎的方法
Nemeth et al. Crohn’s disease and ulcerative colitis show unique cytokine profiles
Khera et al. Race and gender differences in C-reactive protein levels
Hiejima et al. Reduced numbers and proapoptotic features of mucosal-associated invariant T cells as a characteristic finding in patients with inflammatory bowel disease
Baillet et al. Evaluation of serum Interleukin‐6 level as a surrogate marker of synovial inflammation and as a factor of structural progression in early rheumatoid arthritis: results from a French national multicenter cohort
Afsar The relationship between neutrophil lymphocyte ratio with urinary protein albumin excretion in newly diagnosed patients with type 2 diabetes
Vazquez-Oliva et al. Lowering of blood pressure leads to decreased circulating interleukin-6 in hypertensive subjects
Pradeep et al. Association of serum and crevicular visfatin levels in periodontal health and disease with type 2 diabetes mellitus
Lazaridou et al. Association of chronic plaque psoriasis and severe periodontitis: a hospital based case‐control study
Yang et al. Caspase-1 mediated interleukin-18 activation in neutrophils promotes the activity of rheumatoid arthritis in a NLRP3 inflammasome independent manner
Kuo et al. Systemic soluble tumor necrosis factor receptors 1 and 2 are associated with severity of diabetic retinopathy in Hispanics
Colombo et al. Traditional and non traditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: role of vascular endothelial growth factor (VEGATS Study)
Brys et al. Serum interleukin-6 and endotoxin levels and their relationship with fatigue and depressive symptoms in patients on chronic haemodialysis
US20180340225A1 (en) Intestinal metagenomic feature as selection marker of curative effect of acarbose for treating type 2 diabetes
Aly et al. Elevated serum leptin levels in nonobese patients with psoriasis
WO2019122100A1 (en) Workflow for risk assessment and patient management using procalcitonin and midregional-proadrenomedullin
Roerink et al. Cytokine signatures in chronic fatigue syndrome patients: a case control study and the effect of anakinra treatment
Finne Riley et al. Inflammatory markers in endometriosis: reduced peritoneal neutrophil response in minimal endometriosis
An et al. Evaluation of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and mean platelet volume in patients with lichen planus
Chong et al. Serum fractalkine (CX3CL1) concentration correlates with clinical severity in pediatric atopic dermatitis patients
Priø et al. Asymptomatic bacteriuria in elderly humans is associated with increased levels of circulating TNF receptors and elevated numbers of neutrophils
Liu et al. Increased Th17 cells in flow cytometer-sorted CD45RO-positive memory CD4 T cells from patients with systemic lupus erythematosus
Artemniak-Wojtowicz et al. Changes of peripheral Th17 cells subset in overweight and obese children after body weight reduction
Wada et al. Serum-inducible protein (IP)-10 is a disease progression-related marker for non-alcoholic fatty liver disease
Liu et al. Cytokine/chemokine assessment as a complementary diagnostic tool for inflammatory skin diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150325